Universal Beteiligungs und Servicegesellschaft mbH Sells 8,909 Shares of DaVita Inc. $DVA

Universal Beteiligungs und Servicegesellschaft mbH lessened its position in DaVita Inc. (NYSE:DVA) by 19.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 37,075 shares of the company’s stock after selling 8,909 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in DaVita were worth $4,926,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Man Group plc lifted its stake in DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares in the last quarter. Norges Bank purchased a new stake in DaVita in the 2nd quarter worth about $32,986,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in DaVita in the 2nd quarter worth approximately $21,554,000. Arrowstreet Capital Limited Partnership grew its position in shares of DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after purchasing an additional 150,318 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in shares of DaVita by 197.2% in the second quarter. Neuberger Berman Group LLC now owns 194,235 shares of the company’s stock worth $27,669,000 after buying an additional 128,871 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on DVA. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. UBS Group reissued a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Finally, Truist Financial lowered their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research note on Monday, January 5th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus price target of $145.60.

DaVita Stock Down 0.4%

Shares of NYSE:DVA opened at $107.68 on Tuesday. The stock has a market cap of $7.60 billion, a P/E ratio of 11.09, a price-to-earnings-growth ratio of 0.67 and a beta of 0.99. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $179.60. The business’s 50 day moving average is $114.38 and its 200 day moving average is $126.07.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the prior year, the company earned $2.59 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.